CARGO Therapeutics, Inc.
CARGO Therapeutics, Inc. (CRGX): 2 pipeline candidates · ~10 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
9.6 months
D/E 0.09
Lead: Phase 2
2 candidates
N/A
N/A
A transparent, data-derived signal for CARGO Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$108.3M
Quarterly Burn
$77.4M
Runway
9.6 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| firi-cel | Phase 2 |
| fludarabine | Phase 2 |
Frequently asked questions
How many drug candidates are in CARGO Therapeutics, Inc.'s pipeline?
CARGO Therapeutics, Inc. (CRGX) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is CARGO Therapeutics, Inc.'s lead drug candidate?
CARGO Therapeutics, Inc.'s most advanced tracked candidate is firi-cel (Phase 2) for Cancer.
What is CARGO Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, CARGO Therapeutics, Inc. has approximately 9.6 months of cash runway.
Who is the CEO of CARGO Therapeutics, Inc.?
Dear Stockholder is the chief executive officer of CARGO Therapeutics, Inc. (CRGX).
Get the full picture on CARGO Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.